AUTL
Price
$1.15
Change
-$0.07 (-5.79%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
322.02M
21 days until earnings call
OCUL
Price
$6.40
Change
-$0.44 (-6.43%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
1.09B
32 days until earnings call
Ad is loading...

AUTL vs OCUL

Header iconAUTL vs OCUL Comparison
Open Charts AUTL vs OCULBanner chart's image
Autolus Therapeutics
Price$1.15
Change-$0.07 (-5.79%)
Volume$15.8K
Capitalization322.02M
Ocular Therapeutix
Price$6.40
Change-$0.44 (-6.43%)
Volume$24.31K
Capitalization1.09B
AUTL vs OCUL Comparison Chart
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. OCUL commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Hold and OCUL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (AUTL: $1.21 vs. OCUL: $6.84)
Brand notoriety: AUTL and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 364% vs. OCUL: 202%
Market capitalization -- AUTL: $322.02M vs. OCUL: $1.09B
AUTL [@Biotechnology] is valued at $322.02M. OCUL’s [@Biotechnology] market capitalization is $1.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • AUTL’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, both AUTL and OCUL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 3 bullish TA indicator(s).

  • AUTL’s TA Score: 4 bullish, 4 bearish.
  • OCUL’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, AUTL is a better buy in the short-term than OCUL.

Price Growth

AUTL (@Biotechnology) experienced а -14.18% price change this week, while OCUL (@Biotechnology) price change was -6.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

AUTL is expected to report earnings on Jul 31, 2025.

OCUL is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.09B) has a higher market cap than AUTL($322M). OCUL YTD gains are higher at: -19.906 vs. AUTL (-48.511). OCUL has higher annual earnings (EBITDA): -176.14M vs. AUTL (-192.51M). AUTL has more cash in the bank: 657M vs. OCUL (392M). AUTL has less debt than OCUL: AUTL (52.2M) vs OCUL (75.8M). OCUL has higher revenues than AUTL: OCUL (63.7M) vs AUTL (10.1M).
AUTLOCULAUTL / OCUL
Capitalization322M1.09B30%
EBITDA-192.51M-176.14M109%
Gain YTD-48.511-19.906244%
P/E RatioN/AN/A-
Revenue10.1M63.7M16%
Total Cash657M392M168%
Total Debt52.2M75.8M69%
FUNDAMENTALS RATINGS
AUTL vs OCUL: Fundamental Ratings
AUTL
OCUL
OUTLOOK RATING
1..100
766
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
50
Fair valued
PROFIT vs RISK RATING
1..100
10084
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
9686
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUTL's Valuation (30) in the Biotechnology industry is in the same range as OCUL (50) in the Pharmaceuticals Other industry. This means that AUTL’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (84) in the Pharmaceuticals Other industry is in the same range as AUTL (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as AUTL (96) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's Price Growth Rating (86) in the Pharmaceuticals Other industry is in the same range as AUTL (96) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as AUTL (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to AUTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLOCUL
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 14 days ago
84%
Bullish Trend 15 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CHCIX9.99N/A
N/A
AB Discovery Growth I
FSCVX21.45N/A
N/A
Nuveen Small Cap Value C
MRIGX28.85N/A
N/A
Meridian Growth Investor
CGVHX21.20N/A
N/A
American Funds Global Insight 529-F-3
MSPTX11.23N/A
N/A
Morgan Stanley Inst Global Insgt C

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
+2.54%
CRSP - AUTL
41%
Loosely correlated
+11.58%
XENE - AUTL
41%
Loosely correlated
+11.73%
DNLI - AUTL
41%
Loosely correlated
+12.12%
RGNX - AUTL
40%
Loosely correlated
+10.92%
ACLX - AUTL
40%
Loosely correlated
+10.37%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+13.62%
EYPT - OCUL
54%
Loosely correlated
+10.41%
BHVN - OCUL
45%
Loosely correlated
+12.88%
XENE - OCUL
44%
Loosely correlated
+11.73%
APGE - OCUL
43%
Loosely correlated
+10.46%
DNLI - OCUL
42%
Loosely correlated
+12.12%
More